A prospective study on glioblastoma in the elderly

Area of Science:

• Neuro-oncology
• Geriatric Oncology
• Clinical Trials

Background:

• Glioblastoma multiforme disproportionately affects elderly patients.
• Limited prospective trials exist for elderly glioblastoma patients.
• Exclusion of elderly patients from clinical studies is common.

Purpose of the Study:

• To evaluate the efficacy of adjuvant chemotherapy in elderly glioblastoma patients.
• To compare radiotherapy alone, radiotherapy with procarbazine, lomustine, and vincristine (PCV), and radiotherapy with temozolomide.
• To identify prognostic factors for treatment outcomes in this population.

Main Methods:

• A prospective trial involving 79 elderly glioblastoma patients.
• Patients received surgery followed by radiotherapy.
• Three treatment arms: radiotherapy alone (Group A), radiotherapy + PCV chemotherapy (Group B), or radiotherapy + temozolomide chemotherapy (Group C).

Main Results:

• Temozolomide (Group C) significantly improved time to disease progression compared to radiotherapy alone (Group A) and radiotherapy + PCV (Group B).
• Overall survival was significantly better in Group C compared to Group A.
• Karnofsky performance status (KPS) and temozolomide were independent prognostic factors; PCV regimen had higher Grade 3-4 hematologic toxicity.

Conclusions:

• Elderly patients with glioblastoma and good performance status should receive definitive radiation therapy.
• Adjuvant chemotherapy with temozolomide is recommended for this patient group.
• Age should not be a barrier to appropriate glioblastoma treatment.